JP2011502513A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011502513A5 JP2011502513A5 JP2010533204A JP2010533204A JP2011502513A5 JP 2011502513 A5 JP2011502513 A5 JP 2011502513A5 JP 2010533204 A JP2010533204 A JP 2010533204A JP 2010533204 A JP2010533204 A JP 2010533204A JP 2011502513 A5 JP2011502513 A5 JP 2011502513A5
- Authority
- JP
- Japan
- Prior art keywords
- patient
- therapy
- genes
- cancer
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108090000623 proteins and genes Proteins 0.000 claims description 76
- 238000011122 anti-angiogenic therapy Methods 0.000 claims description 54
- 239000000523 sample Substances 0.000 claims description 36
- 150000001875 compounds Chemical class 0.000 claims description 35
- 238000011319 anticancer therapy Methods 0.000 claims description 34
- 238000000034 method Methods 0.000 claims description 33
- 230000008901 benefit Effects 0.000 claims description 23
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 18
- 206010038389 Renal cancer Diseases 0.000 claims description 18
- 201000010982 kidney cancer Diseases 0.000 claims description 18
- 206010028980 Neoplasm Diseases 0.000 claims description 12
- 239000013074 reference sample Substances 0.000 claims description 12
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 8
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 8
- 239000005557 antagonist Substances 0.000 claims description 8
- 102000040430 polynucleotide Human genes 0.000 claims description 8
- 108091033319 polynucleotide Proteins 0.000 claims description 8
- 239000002157 polynucleotide Substances 0.000 claims description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 230000004043 responsiveness Effects 0.000 claims description 6
- 238000002560 therapeutic procedure Methods 0.000 claims description 6
- 229960000397 bevacizumab Drugs 0.000 claims description 4
- 230000004083 survival effect Effects 0.000 claims description 4
- 229940124650 anti-cancer therapies Drugs 0.000 claims description 3
- 238000011331 genomic analysis Methods 0.000 claims description 2
- 238000012544 monitoring process Methods 0.000 claims description 2
- 230000009467 reduction Effects 0.000 claims description 2
- 230000004044 response Effects 0.000 claims description 2
- 238000011282 treatment Methods 0.000 claims description 2
- 230000002491 angiogenic effect Effects 0.000 claims 2
- 230000008569 process Effects 0.000 claims 2
- 230000033115 angiogenesis Effects 0.000 claims 1
- 230000002137 anti-vascular effect Effects 0.000 claims 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98688407P | 2007-11-09 | 2007-11-09 | |
| PCT/US2008/082456 WO2009061800A2 (en) | 2007-11-09 | 2008-11-05 | Methods and compositions for diagnostic use in cancer patients |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011502513A JP2011502513A (ja) | 2011-01-27 |
| JP2011502513A5 true JP2011502513A5 (enExample) | 2012-12-27 |
Family
ID=40342593
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010533204A Withdrawn JP2011502513A (ja) | 2007-11-09 | 2008-11-05 | 癌患者における診断用途のための方法および組成物 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20090123930A1 (enExample) |
| EP (1) | EP2222874A2 (enExample) |
| JP (1) | JP2011502513A (enExample) |
| KR (1) | KR20100095571A (enExample) |
| CN (1) | CN101910416A (enExample) |
| AU (1) | AU2008324782A1 (enExample) |
| BR (1) | BRPI0817158A2 (enExample) |
| CA (1) | CA2703258A1 (enExample) |
| IL (1) | IL205246A0 (enExample) |
| MX (1) | MX2010005057A (enExample) |
| RU (1) | RU2010123381A (enExample) |
| WO (1) | WO2009061800A2 (enExample) |
| ZA (1) | ZA201002808B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG177640A1 (en) * | 2009-07-13 | 2012-02-28 | Genentech Inc | Diagnostic methods and compositions for treatment of cancer |
| KR101557545B1 (ko) * | 2009-09-17 | 2015-10-06 | 에프. 호프만-라 로슈 아게 | 암 환자에서 진단 용도를 위한 방법 및 조성물 |
| CN104634971A (zh) * | 2010-07-19 | 2015-05-20 | 霍夫曼-拉罗奇有限公司 | 鉴定响应抗癌疗法的可能性升高的患者的方法 |
| WO2012010549A1 (en) * | 2010-07-19 | 2012-01-26 | F. Hoffmann-La Roche Ag | Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy |
| US10260097B2 (en) | 2011-06-02 | 2019-04-16 | Almac Diagnostics Limited | Method of using a gene expression profile to determine cancer responsiveness to an anti-angiogenic agent |
| CA2862835A1 (en) * | 2012-01-13 | 2013-07-18 | Genentech, Inc. | Biological markers for identifying patients for treatment with vegf antagonists |
| WO2014001232A1 (en) * | 2012-06-26 | 2014-01-03 | F. Hoffmann-La Roche Ag | Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer |
| HK1214633A1 (zh) * | 2012-12-03 | 2016-07-29 | Almac Diagnostics Limited | 癌症的分子诊断测试 |
| US11015190B2 (en) | 2013-09-17 | 2021-05-25 | Lucence Life Sciences Pte Ltd | Method of treating a patient having renal cancer |
| GB201409479D0 (en) * | 2014-05-28 | 2014-07-09 | Almac Diagnostics Ltd | Molecular diagnostic test for cancer |
| MX2017007535A (es) * | 2014-12-09 | 2017-08-10 | Merck Sharp & Dohme | Sistema y metodos para derivar biomarcadores de firmas geneticas de la respuesta a antagonistas de muerte programada 1 (pd-1). |
| KR101903522B1 (ko) * | 2015-11-25 | 2018-11-23 | 한국전자통신연구원 | 다차원 건강데이터에 대한 유사사례 검색 방법 및 그 장치 |
| WO2025098316A1 (en) * | 2023-11-09 | 2025-05-15 | Sun Jet Biotechnology Inc. | Apolipoprotein a-ii biomarkers for detecting and monitoring cancers |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030027216A1 (en) * | 2001-07-02 | 2003-02-06 | Kiernan Urban A. | Analysis of proteins from biological fluids using mass spectrometric immunoassay |
| EP1869216B1 (en) * | 2005-04-13 | 2012-08-15 | Oncotest GmbH | Gene expression profiles being predictive for the response of tumors to pharmaceutically effective compounds |
| WO2007123722A2 (en) * | 2006-03-31 | 2007-11-01 | Bayer Healthcare Llc | Methods for prediction and prognosis of cancer, and monitoring cancer therapy |
-
2008
- 2008-11-05 WO PCT/US2008/082456 patent/WO2009061800A2/en not_active Ceased
- 2008-11-05 KR KR1020107012551A patent/KR20100095571A/ko not_active Withdrawn
- 2008-11-05 BR BRPI0817158 patent/BRPI0817158A2/pt not_active IP Right Cessation
- 2008-11-05 AU AU2008324782A patent/AU2008324782A1/en not_active Abandoned
- 2008-11-05 JP JP2010533204A patent/JP2011502513A/ja not_active Withdrawn
- 2008-11-05 EP EP08846956A patent/EP2222874A2/en not_active Withdrawn
- 2008-11-05 RU RU2010123381/15A patent/RU2010123381A/ru not_active Application Discontinuation
- 2008-11-05 US US12/265,143 patent/US20090123930A1/en not_active Abandoned
- 2008-11-05 CN CN2008801243215A patent/CN101910416A/zh active Pending
- 2008-11-05 MX MX2010005057A patent/MX2010005057A/es not_active Application Discontinuation
- 2008-11-05 CA CA2703258A patent/CA2703258A1/en not_active Abandoned
-
2010
- 2010-04-21 ZA ZA2010/02808A patent/ZA201002808B/en unknown
- 2010-04-22 IL IL205246A patent/IL205246A0/en unknown
- 2010-11-19 US US12/950,824 patent/US20110151468A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lambrechts et al. | Markers of response for the antiangiogenic agent bevacizumab | |
| Beuselinck et al. | Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib | |
| Fujii et al. | Identification and monitoring of mutations in circulating cell-free tumor DNA in hepatocellular carcinoma treated with lenvatinib | |
| Voorwerk et al. | PD-L1 blockade in combination with carboplatin as immune induction in metastatic lobular breast cancer: the GELATO trial | |
| Formica et al. | Predictive value of VEGF gene polymorphisms for metastatic colorectal cancer patients receiving first-line treatment including fluorouracil, irinotecan, and bevacizumab | |
| RU2010123381A (ru) | Способ и композиции для диагностического применения у раковых пациентов | |
| JP2007507222A5 (enExample) | ||
| JP2014520529A5 (enExample) | ||
| US20120015906A1 (en) | Uses of bortezomib in predicting survival in multiple myeloma patients | |
| Kiss et al. | MicroRNAs as outcome predictors in patients with metastatic colorectal cancer treated with bevacizumab in combination with FOLFOX | |
| JP2015526074A5 (enExample) | ||
| Wang et al. | Molecular tracing of prostate cancer lethality | |
| Beuselinck et al. | Validation of VEGFR 1 rs9582036 as predictive biomarker in metastatic clear‐cell renal cell carcinoma patients treated with sunitinib | |
| JP2017525337A5 (enExample) | ||
| Beuselinck et al. | RANK/OPG ratio of expression in primary clear-cell renal cell carcinoma is associated with bone metastasis and prognosis in patients treated with anti-VEGFR-TKIs | |
| JP2015210268A (ja) | 癌治療 | |
| Kovacova et al. | MiR-376b-3p is associated with long-term response to sunitinib in metastatic renal cell carcinoma patients | |
| Nam et al. | Identification of a novel MicroRNA panel associated with metastasis following radical prostatectomy for prostate cancer | |
| Puente et al. | Novel potential predictive markers of sunitinib outcomes in long-term responders versus primary refractory patients with metastatic clear-cell renal cell carcinoma | |
| Heo et al. | The efficacy of immune checkpoint inhibitors in anaplastic lymphoma kinase‐positive non‐small cell lung cancer | |
| Yin et al. | The evolving process of ferroptosis in thyroid cancer: Novel mechanisms and opportunities | |
| Buchbinder et al. | Biomarkers in melanoma: Lessons from translational medicine | |
| Zhao et al. | Advances in predictive biomarkers for anti-angiogenic therapy in non-small cell lung cancer | |
| JP2019533987A5 (enExample) | ||
| Andrade de Mello et al. | Insights into angiogenesis in non-small cell lung cancer: molecular mechanisms, polymorphic genes, and targeted therapies |